DDrare: Database of Drug Development for Rare Diseases

7. 大脳皮質基底核変性症
［臨床試験数：16，薬物数：33（DrugBank：11），標的遺伝子数：6，標的パスウェイ数：13］

Searched query = "Corticobasal degeneration", "Corticobasal syndrome", "CBD"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = 18F-AV-1451; 18F-FDG; 18F-RO6958948; ABBV-8E12; AL; Anti-Parkinson medication; BIIB092; BOTULINUM TOXIN TYPE A; Botulinum toxin type A; Davunetide; Davunetide (AL-108, NAP); Device: Deep Brain Stimulation; Diagnostic Test: Elecsys (Roche) Abeta42, Ttau and Ptau; Diagnostic Test: Flutemetamol F18 Injection; Diagnostic Test: Lumipulse (Fujirebio) Abeta42, Ttau and Ptau; Diagnostic Test: [18F]-RO6958948; Dopamine; Flortaucipir; Flortaucipir F18; Flutemetamol; Flutemetamol F18; Leucine; Lithium; NT 101; Other: 13C6 Leucine; Procedure: Brain PET scan; Raclopride; TPI 287 2 mg/m2; TPI-287 20 mg/m2; TPI-287 6.3 mg/m2; Vizamyl; Vizamyl (flutemetamol(F-18)); Xeomin

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2014-000422-38-SE (EUCTR)	19/09/2014	05/08/2014	A study evaluating the diagnostic accuracy of [18F]-AV-1451 PET to detect and distinguish neurodegenerative disorders characterized by cerebral accumulation of the protein tau	An open-label study evaluating the diagnostic accuracy of [18F]-AV-1451 PET to detect and distinguish neurodegenerative disorders characterized by cerebral accumulation of tau	Neurodegenerative disorders with Tau-pathology; including Alzheimer's disease, progressive supranuclear palsy, frontotemporal dementia, corticobasal degeneration and important differential diagnostic conditions. MedDRA version: 17.0;Level: HLT;Classification code 10001897;Term: Alzheimer's disease (incl subtypes);System Organ Class: 10029205 - Nervous system disorders MedDRA version: 17.0;Level: PT;Classification code 10053643;Term: Neurodegenerative disorder;Level: LLT;Classification code 10009846;Term: Cognitive impairment;Classification code 10001896;Term: Alzheimer's disease;Classification code 10012285;Term: Dementia due to Pick's disease;Classification code 10012267;Term: Dementia;Classification code 10067889;Term: Dementia with Lewy bodies;Classification code 10036813;Term: Progressive supranuclear palsy;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Diagnosis [E01]	Product Name: 18F-AV-1451	Skåne University Hospital, Region Skåne	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes			Sweden
2	NCT02167594 (ClinicalTrials.gov)	August 12, 2014	17/6/2014	Tau Imaging in Subjects With Progressive Supranuclear Palsy, Corticobasal Degeneration and Healthy Volunteers	18F-AV-1451 Injection for Brain Imaging of Tau in Subjects With Progressive Supranuclear Palsy (PSP), Subjects With Corticobasal Degeneration (CBD) and Healthy Volunteers	Progressive Supranuclear Palsy;Corticobasal Degeneration	Drug: Flortaucipir F18;Procedure: Brain PET scan	Avid Radiopharmaceuticals	NULL	Completed	50 Years	85 Years	All	29	Phase 1	United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

EUCTR2014-000422-38-SE
(EUCTR)

19/09/2014

05/08/2014

A study evaluating the diagnostic accuracy of [18F]-AV-1451 PET to detect and distinguish neurodegenerative disorders characterized by cerebral accumulation of the protein tau

An open-label study evaluating the diagnostic accuracy of [18F]-AV-1451 PET to detect and distinguish neurodegenerative disorders characterized by cerebral accumulation of tau

Neurodegenerative disorders with Tau-pathology; including Alzheimer's disease, progressive supranuclear palsy, frontotemporal dementia, corticobasal degeneration and important differential diagnostic conditions.
MedDRA version: 17.0;Level: HLT;Classification code 10001897;Term: Alzheimer's disease (incl subtypes);System Organ Class: 10029205 - Nervous system disorders
MedDRA version: 17.0;Level: PT;Classification code 10053643;Term: Neurodegenerative disorder;Level: LLT;Classification code 10009846;Term: Cognitive impairment;Classification code 10001896;Term: Alzheimer's disease;Classification code 10012285;Term: Dementia due to Pick's disease;Classification code 10012267;Term: Dementia;Classification code 10067889;Term: Dementia with Lewy bodies;Classification code 10036813;Term: Progressive supranuclear palsy;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Diagnosis [E01]

Product Name: 18F-AV-1451

Skåne University Hospital, Region Skåne

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

Sweden

NCT02167594
(ClinicalTrials.gov)

August 12, 2014

17/6/2014

Tau Imaging in Subjects With Progressive Supranuclear Palsy, Corticobasal Degeneration and Healthy Volunteers

18F-AV-1451 Injection for Brain Imaging of Tau in Subjects With Progressive Supranuclear Palsy (PSP), Subjects With Corticobasal Degeneration (CBD) and Healthy Volunteers

Progressive Supranuclear Palsy;Corticobasal Degeneration

Drug: Flortaucipir F18;Procedure: Brain PET scan

Avid Radiopharmaceuticals

NULL

Completed

50 Years

85 Years

All

Phase 1

United States